{"id":"NCT00082381","sponsor":"AstraZeneca","briefTitle":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","officialTitle":"Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2004-05-11","resultsPosted":"2013-07-31","lastUpdate":"2015-04-07"},"enrollment":551,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Exenatide (AC2993)","otherNames":["Byetta"]},{"type":"DRUG","name":"Insulin glargine","otherNames":["Lantus"]}],"arms":[{"label":"Exenatide Arm","type":"EXPERIMENTAL"},{"label":"Insulin Glargine Arm","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).","primaryOutcome":{"measure":"Change in Glycosylated Hemoglobin (HbA1c)","timeFrame":"Baseline, week 26","effectByArm":[{"arm":"Exenatide Arm","deltaMin":8.13,"sd":0.07},{"arm":"Insulin Glargine Arm","deltaMin":8.19,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4602"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":91,"countries":["United States","Australia","Belgium","Brazil","Finland","Germany","Netherlands","Norway","Poland","Portugal","Puerto Rico","Spain","Sweden"]},"refs":{"pmids":["16230722","22913891","22236356"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Hypoglycemia","Nausea","Vomiting","Headache","Nasopharyngitis"]}}